NEW YORK (GenomeWeb) – Tempus and University of Chicago Medicine announced today that they have partnered to study clinical and molecular data from pancreatic cancer patients in order to improve the prediction of treatment responses.
Under the terms of their alliance, Tempus will combine information from its own database with genomic data, biospecimens, and clinical information from more than 300 pancreatic cancer patients collected by the university's Chicago Pancreatic Cancer Initiative (CPCI). The company will then use bioinformatics and machine learning to analyze these data, as well as to generate additional genomic data using its technologies.
Additional terms were not disclosed.
"The University of Chicago and Tempus share a commitment to accelerate pancreatic cancer research and identify treatments that can improve the lives of those diagnosed," CPCI researcher and Tempus collaborator Ralph Weichselbaum said in a statement. "We are optimistic that this collaboration can make a difference in the lives of those diagnosed and treated for pancreatic cancer."
Earlier this month, Tempus formed a similar alliance with the University of Michigan focused on breast cancer. And in March, Tempus partnered with the University of Chicago Medicine to perform molecular sequencing on about 1,000 breast cancer patients.